Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
- Lankheet, N.
- Kloth, J.S.
- Gadellaa-van Hooijdonk, C.G.M.
- Cirkel, G.A.
- Mathijssen, R.H.
- Lolkema, M.P.
- Schellens, J.H.
- Voest, E.E.
- Sleijfer, S.
- Jonge, M.J. de
- Haanen, J.B.
- Beijnen, J.H.
- Huitema, A.D.
- Steeghs, N.
DOIAbstract
Contains fulltext : 136010.pdf (publisher's version ) (Open Access)Background:Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels.Methods:Patients were treated with sunitinib 37.5 mg once daily. At days 15 and 29 of treatment, plasma trough levels of sunitinib and N-desethyl sunitinib were measured. If the total trough level (TTL) was <50 ng ml(-1) and the patient did not show any grade 3 toxicity, the daily sunitinib dose was increased by 12.5 mg. If the patient suffered from grade 3 toxicity, the sunitinib dose was lowered by 12.5 mg.Results:Twenty-nine out of 43 patients were ...
Add to ORKG